Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 15 de 15
Filtrer
Plus de filtres










Base de données
Gamme d'année
1.
Pathol Res Pract ; 254: 155161, 2024 Feb.
Article de Anglais | MEDLINE | ID: mdl-38280275

RÉSUMÉ

Chronic Myeloid Leukemia (CML) is characterized by chromosomal aberrations involving the fusion of the BCR and ABL genes on chromosome 22, resulting from a reciprocal translocation between chromosomes 9 and 22. This fusion gives rise to the oncogenic BCR-ABL, an aberrant tyrosine kinase identified as Abl protein. The Abl protein intricately regulates the cell cycle by phosphorylating protein tyrosine residues through diverse signaling pathways. In CML, the BCR-ABL fusion protein disrupts the first exon of Abl, leading to sustained activation of tyrosine kinase and resistance to deactivation mechanisms. Pharmacological interventions, such as imatinib, effectively target BCR-ABL's tyrosine kinase activity by binding near the active site, disrupting ATP binding, and inhibiting downstream protein phosphorylation. Nevertheless, the emergence of resistance, often attributed to cap structure mutations, poses a challenge to imatinib efficacy. Current research endeavours are directed towards overcoming resistance and investigating innovative therapeutic strategies. This article offers a comprehensive analysis of the structural attributes of BCR-ABL, emphasizing its pivotal role as a biomarker and therapeutic target in CML. It underscores the imperative for ongoing research to refine treatment modalities and enhance overall outcomes in managing CML.


Sujet(s)
Gènes abl , Leucémie myéloïde chronique BCR-ABL positive , Humains , Mésilate d'imatinib/usage thérapeutique , Mésilate d'imatinib/pharmacologie , Pyrimidines/usage thérapeutique , Pipérazines/usage thérapeutique , Benzamides/pharmacologie , Benzamides/usage thérapeutique , Résistance aux médicaments antinéoplasiques/génétique , Leucémie myéloïde chronique BCR-ABL positive/traitement médicamenteux , Leucémie myéloïde chronique BCR-ABL positive/génétique , Leucémie myéloïde chronique BCR-ABL positive/métabolisme , Protéines de fusion bcr-abl/génétique , Protéines de fusion bcr-abl/métabolisme , Protéines de fusion bcr-abl/pharmacologie , Inhibiteurs de protéines kinases/usage thérapeutique , Inhibiteurs de protéines kinases/pharmacologie
2.
Cell Signal ; 101: 110492, 2023 01.
Article de Anglais | MEDLINE | ID: mdl-36241056

RÉSUMÉ

In recent decades, there has been a significant amount of research into breast cancer, with some important breakthroughs in the treatment of both primary and metastatic breast cancers. It's a well-known fact that treating breast cancer is still a challenging endeavour even though physicians have a fantastic toolset of the latest treatment options at their disposal. Due to limitations of current clinical treatment options, traditional chemotherapeutic drugs, and surgical options are still required to address this condition. In recent years, there have been several developments resulting in a wide range of treatment options. This review article discusses the cellular and molecular foundation of chemotherapeutic drugs, endocrine system-based treatments, biological therapies, gene therapy, and innovative techniques for treating breast cancer.


Sujet(s)
Tumeurs du sein , Humains , Femelle , Tumeurs du sein/thérapie , Tumeurs du sein/traitement médicamenteux
3.
Life Sci ; 310: 121046, 2022 Dec 01.
Article de Anglais | MEDLINE | ID: mdl-36209829

RÉSUMÉ

RAS-related nuclear protein(RAN) is a nuclear shuttle and normally regulates events in the cell cycle. When overexpressed in cultured cells, it causes increases in cell migration/invasion in vitro and its overexpression is associated with early breast cancer patient deaths in vivo. However, the underlying mechanism is unknown. The effect of RAN overexpression on potential targets MMP2, ATF3, CXCR3 was investigated by Real-Time PCR/Western blots in the triple receptor negative breast cancer(TRNBC) cell line MDA-MB231 and consequent biological effects were measured by cell adhesion, cell migration and cell invasion assays. Results showed that knockdown of RAN lead to a reduction of MMP2 and its potential regulators ATF3 and CXCR3. Moreover, knockdown of ATF3 or CXCR3 downregulated MMP2 without affecting RAN, indicating that RAN regulates MMP2 through ATF3 and CXCR3. Knockdown of RAN and MMP2 reduced cell adhesion, cell migration and cell growth in agar, whilst overexpression of MMP2 reversed the knockdown of RAN. Furthermore, immunohistochemical staining for RAN and MMP2 are positively associated with each other in the same tumour and separately with patient survival times in breast cancer specimens, suggesting that a high level of RAN may be a pre-requisite for MMP2 overexpression and metastasis. Moreover, positive immunohistochemical staining for both RAN and MMP-2 reduces further patient survival times over that for either protein separately. Our results suggest that MMP2 expression can stratify progression of breast cancers with a high and low incidence of RAN, both RAN and MMP2 in combination can be used for a more accurate patient prognosis. SIMPLE SUMMARY: Ran is an important regulator of normal cell growth and behaviour. We have established in cell line models of breast cancer (BC) a molecular pathway between RAN and its protein-degrading effector MMP-2 and properties related to metastasis in culture. Using immunohistochemistry (IHC) staining of primary BCs, we have shown that RAN and MMP-2 are on their own significantly associated with patient demise from metastatic BC. Moreover, when staining for MMP-2 is added to that for RAN in the primary tumours, there is a significant decrease in patient survival time over that for either protein alone. Thus a combination of staining for RAN and MMP2 is an excellent marker for poor prognosis in breast cancer.


Sujet(s)
Tumeurs du sein , Matrix metalloproteinase 2 , Tumeurs du sein triple-négatives , Protéine G ran , Femelle , Humains , Tumeurs du sein/anatomopathologie , Lignée cellulaire tumorale , Mouvement cellulaire , Régulation de l'expression des gènes tumoraux , Guanosine triphosphate , Matrix metalloproteinase 2/métabolisme , Invasion tumorale , Protéine G ran/génétique , Protéine G ran/métabolisme , Tumeurs du sein triple-négatives/anatomopathologie
4.
Future Oncol ; 13(15): 1345-1358, 2017 Jun.
Article de Anglais | MEDLINE | ID: mdl-28589766

RÉSUMÉ

Currently, out of the 82 US FDA-approved targeted therapies for adult cancer treatments, only three are approved for use in children irrespective of their genomic status. Apart from leukemia, only a handful of genomic-based trials involving children with solid tumors are ongoing. Emerging genomic data for pediatric solid tumors may facilitate the development of precision medicine in pediatric patients. Here, we provide an up-to-date review of all reported genomic aberrations in the eight most common pediatric solid tumors with whole-exome sequencing or whole-genome sequencing data (from cBioPortal database, Pediatric Cancer Genome Project, Therapeutically Applicable Research to Generate Effective Treatments) and additional non-whole-exome sequencing studies. Potential druggable events are highlighted and discussed so as to facilitate preclinical and clinical research in this area.


Sujet(s)
Antinéoplasiques/usage thérapeutique , Thérapie moléculaire ciblée/méthodes , Tumeurs/traitement médicamenteux , Médecine de précision/méthodes , Enfant , Exome/génétique , Génomique , Humains , Mutation , Tumeurs/génétique , Évaluation de la réponse des tumeurs solides aux traitements , Analyse de séquence d'ADN ,
6.
Br J Cancer ; 115(8): 1000-1007, 2016 10 11.
Article de Anglais | MEDLINE | ID: mdl-27607470

RÉSUMÉ

BACKGROUND: Soft tissue sarcomas are heterogeneous and a major complication in their management is that the existing classification scheme is not definitive and is still evolving. Leiomyosarcomas, a major histologic category of soft tissue sarcomas, are malignant tumours displaying smooth muscle differentiation. Although defined as a single group, they exhibit a wide range of clinical behaviour. We aimed to carry out molecular classification to identify new molecular subgroups with clinical relevance. METHODS: We used gene expression profiling on 20 extra-uterine leiomyosarcomas and cross-study analyses for molecular classification of leiomyosarcomas. Clinical significance of the subgroupings was investigated. RESULTS: We have identified two distinct molecular subgroups of leiomyosarcomas. One group was characterised by high expression of 26 genes that included many genes from the sub-classification gene cluster proposed by Nielsen et al. These sub-classification genes include genes that have importance structurally, as well as in cell signalling. Notably, we found a statistically significant association of the subgroupings with tumour grade. Further refinement led to a group of 15 genes that could recapitulate the tumour subgroupings in our data set and in a second independent sarcoma set. Remarkably, cross-study analyses suggested that these molecular subgroups could be found in four independent data sets, providing strong support for their existence. CONCLUSIONS: Our study strongly supported the existence of distinct leiomyosarcoma molecular subgroups, which have clinical association with tumour grade. Our findings will aid in advancing the classification of leiomyosarcomas and lead to more individualised and better management of the disease.


Sujet(s)
Analyse de profil d'expression de gènes , Régulation de l'expression des gènes tumoraux , Léiomyosarcome/classification , Tumeurs de l'abdomen/génétique , Sujet âgé , Jeux de données comme sujet , Membres , Femelle , Humains , Léiomyosarcome/génétique , Mâle , Adulte d'âge moyen , Grading des tumeurs , Protéines tumorales/biosynthèse , Protéines tumorales/génétique , Tumeurs du rétropéritoine/génétique , Tumeurs du thorax/génétique , Analyse sur puce à tissus
7.
J Biol Chem ; 286(7): 5884-94, 2011 Feb 18.
Article de Anglais | MEDLINE | ID: mdl-21156792

RÉSUMÉ

Ovalbumin (OVA), a non-inhibitory member of the serpin superfamily, forms fibrillar aggregates upon heat-induced denaturation. Recent studies suggested that OVA fibrils are generated by a mechanism similar to that of amyloid fibril formation, which is distinct from polymerization mechanisms proposed for other serpins. In this study, we provide new insights into the mechanism of OVA fibril formation through identification of amyloidogenic core regions using synthetic peptide fragments, site-directed mutagenesis, and limited proteolysis. OVA possesses a single disulfide bond between Cys(73) and Cys(120) in the N-terminal helical region of the protein. Heat treatment of disulfide-reduced OVA resulted in the formation of long straight fibrils that are distinct from the semiflexible fibrils formed from OVA with an intact disulfide. Computer predictions suggest that helix B (hB) of the N-terminal region, strand 3A, and strands 4-5B are highly ß-aggregation-prone regions. These predictions were confirmed by the fact that synthetic peptides corresponding to these regions formed amyloid fibrils. Site-directed mutagenesis of OVA indicated that V41A substitution in hB interfered with the formation of fibrils. Co-incubation of a soluble peptide fragment of hB with the disulfide-intact full-length OVA consistently promoted formation of long straight fibrils. In addition, the N-terminal helical region of the heat-induced fibril of OVA was protected from limited proteolysis. These results indicate that the heat-induced fibril formation of OVA occurs by a mechanism involving transformation of the N-terminal helical region of the protein to ß-strands, thereby forming sequential intermolecular linkages.


Sujet(s)
Amyloïde/composition chimique , Ovalbumine/composition chimique , Peptides/composition chimique , Amyloïde/génétique , Animaux , Poulets , Cystéine/composition chimique , Cystéine/génétique , Disulfures/composition chimique , Mutagenèse dirigée , Ovalbumine/génétique , Peptides/génétique , Structure quaternaire des protéines , Structure secondaire des protéines
8.
Cancer Res ; 70(7): 2984-93, 2010 Apr 01.
Article de Anglais | MEDLINE | ID: mdl-20233878

RÉSUMÉ

The effectiveness of radiotherapy treatment could be significantly improved if tumor cells could be rendered more sensitive to ionizing radiation (IR) without altering the sensitivity of normal tissues. However, many of the key therapeutically exploitable mechanisms that determine intrinsic tumor radiosensitivity are largely unknown. We have conducted a small interfering RNA (siRNA) screen of 200 genes involved in DNA damage repair aimed at identifying genes whose knockdown increased tumor radiosensitivity. Parallel siRNA screens were conducted in irradiated and unirradiated tumor cells (SQ20B) and irradiated normal tissue cells (MRC5). Using gammaH2AX foci at 24 hours after IR, we identified several genes, such as BRCA2, Lig IV, and XRCC5, whose knockdown is known to cause increased cell radiosensitivity, thereby validating the primary screening end point. In addition, we identified POLQ (DNA polymerase ) as a potential tumor-specific target. Subsequent investigations showed that POLQ knockdown resulted in radiosensitization of a panel of tumor cell lines from different primary sites while having little or no effect on normal tissue cell lines. These findings raise the possibility that POLQ inhibition might be used clinically to cause tumor-specific radiosensitization.


Sujet(s)
Réparation de l'ADN/génétique , DNA-directed DNA polymerase/génétique , Tumeurs/génétique , Tumeurs/radiothérapie , Petit ARN interférent/génétique , Antinéoplasiques alcoylants/pharmacologie , Lignée cellulaire tumorale , Survie cellulaire/génétique , Survie cellulaire/effets des radiations , DNA-directed DNA polymerase/déficit , DNA-directed DNA polymerase/métabolisme , Dacarbazine/analogues et dérivés , Dacarbazine/pharmacologie , Techniques de knock-down de gènes , Cellules HeLa , Histone , Humains , Rayons infrarouges , Tumeurs/traitement médicamenteux , Radiotolérance/génétique , Témozolomide , Transfection ,
9.
Blood ; 115(8): 1490-9, 2010 Feb 25.
Article de Anglais | MEDLINE | ID: mdl-20042721

RÉSUMÉ

Chromosomal translocations involving the immunoglobulin heavy chain (IGH) locus define common subgroups of B-cell lymphoma but are rare in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Recent fluorescent in situ hybridization and molecular cloning studies have identified several novel IGH translocations involving genes that play important roles in normal hemopoiesis, including the cytokine receptor genes CRLF2 and EPOR, all members of the CCAAT enhancer-binding protein gene family, as well as genes not normally expressed in hemopoietic cells including inhibitor of DNA binding 4. IGH translocation results in deregulated target gene expression because of juxtaposition with IGH transcriptional enhancers. However, many genes targeted by IGH translocations are also more commonly deregulated in BCP-ALL as a consequence of other genetic or epigenetic mechanisms. For example, interstitial genomic deletions also result in deregulated CRLF2 expression, whereas EPOR expression is deregulated as a consequence of the ETV6-RUNX1 fusion. The possible clinical importance of many of the various IGH translocations in BCP-ALL remains to be determined from prospective studies, but CRLF2 expression is associated with a poor prognosis. Despite their rarity, IGH chromosomal translocations in BCP-ALL therefore define not only new mechanisms of B-cell transformation but also clinically important subgroups of disease and suggest new targeted therapeutic approaches.


Sujet(s)
Lymphocytes B/métabolisme , Transformation cellulaire néoplasique/métabolisme , Chaines lourdes des immunoglobulines/métabolisme , Leucémie-lymphome lymphoblastique à précurseurs B/métabolisme , Locus de caractère quantitatif , Translocation génétique , Maladie aigüe , Animaux , Transformation cellulaire néoplasique/génétique , Sous-unité alpha 2 du facteur CBF/biosynthèse , Sous-unité alpha 2 du facteur CBF/génétique , Régulation de l'expression des gènes dans la leucémie/génétique , Hématopoïèse/génétique , Humains , Chaines lourdes des immunoglobulines/génétique , Protéines d'inhibition de la différenciation/biosynthèse , Protéines d'inhibition de la différenciation/génétique , Protéines de fusion oncogènes/biosynthèse , Protéines de fusion oncogènes/génétique , Leucémie-lymphome lymphoblastique à précurseurs B/diagnostic , Leucémie-lymphome lymphoblastique à précurseurs B/génétique , Leucémie-lymphome lymphoblastique à précurseurs B/thérapie , Pronostic , Récepteurs aux cytokines/biosynthèse , Récepteurs aux cytokines/génétique , Récepteur érythropoïétine/biosynthèse , Récepteur érythropoïétine/génétique
10.
Nucleic Acids Res ; 37(19): 6400-13, 2009 Oct.
Article de Anglais | MEDLINE | ID: mdl-19713438

RÉSUMÉ

Both the ERCC1-XPF complex and the proteins involved in homoIogous recombination (HR) have critical roles in inter-strand cross-link (ICL) repair. Here, we report that mitomycin C-induced lesions inhibit replication fork elongation. Furthermore, mitomycin C-induced DNA double-strand breaks (DSBs) are the result of the collapse of ICL-stalled replication forks. These are not formed through replication run off, as we show that mitomycin C or cisplatin-induced DNA lesions are not incised by global genome nucleotide excision repair (GGR). We also suggest that ICL-lesion repair is initiated either by replication or transcription, as the GGR does not incise ICL-lesions. Furthermore, we report that RAD51 foci are induced by cisplatin or mitomycin C independently of ERCC1, but that mitomycin C-induced HR measured in a reporter construct is impaired in ERCC1-defective cells. These data suggest that ERCC1-XPF plays a role in completion of HR in ICL repair. We also find no additional sensitivity to cisplatin by siRNA co-depletion of XRCC3 and ERCC1, showing that the two proteins act on the same pathway to promote survival.


Sujet(s)
Réactifs réticulants/toxicité , Réparation de l'ADN , Protéines de liaison à l'ADN/métabolisme , Endonucleases/métabolisme , Recombinaison génétique , Animaux , Lignée cellulaire , Cisplatine/toxicité , Cricetinae , Cassures double-brin de l'ADN , Réplication de l'ADN/effets des médicaments et des substances chimiques , Humains , Mitomycine/toxicité , Mutation , Rad51 Recombinase/génétique
11.
ACS Appl Mater Interfaces ; 1(2): 228-31, 2009 Feb.
Article de Anglais | MEDLINE | ID: mdl-20353205

RÉSUMÉ

We developed a unique method for converting atmospheric aldehyde into alcohol using formaldehyde dehydrogenase from Pseudomonas putida (PFDH) doped in a polymer film. A film of poly(2-methacryloyloxyethylphosphorylcholine-co-n-butyl methacrylate) (PMB), which has a chemical structure similar to that of a biological membrane, was employed for its biocompatibility. A water-incorporated polymer film entrapping PFDH and its cofactor NAD(+) was obtained by drying a buffered solution of PMB, PFDH, and NAD(+). The aldehydes in the air were absorbed into the polymer film and then enzymatically oxidized by PFDH doped in the PMB film. Interestingly, alcohol and carboxylic acid were produced by the enzymatic reaction, indicating that PFDH catalyzes dismutation of aldehyde in the PMB film. Importantly, a PFDH-PMB film catalyzes aldehyde degradation without consuming the nucleotide cofactor, thereby allowing repeated use of the film. The activity of PFDH in the PMB film was higher than that in other common water-soluble polymers, suggesting that the hydrational state in a phospholipid polymer matrix is suitable for enzymatic activity.


Sujet(s)
Alcools/synthèse chimique , Aldehyde oxidoreductases/composition chimique , Aldéhydes/composition chimique , Enzymes immobilisées/composition chimique , Méthacrylates/composition chimique , Phospholipides/composition chimique , Phosphoryl-choline/analogues et dérivés , Alcools/composition chimique , Alcools/métabolisme , Aldehyde oxidoreductases/métabolisme , Aldéhydes/métabolisme , Enzymes immobilisées/métabolisme , Gaz/composition chimique , Gaz/métabolisme , NAD/composition chimique , NAD/métabolisme , Phosphoryl-choline/composition chimique , Pseudomonas putida/enzymologie
12.
Biochemistry ; 47(9): 2961-7, 2008 Mar 04.
Article de Anglais | MEDLINE | ID: mdl-18232642

RÉSUMÉ

AlphaA-crystallin (alphaAC), a major component of eye lens, exhibits chaperone-like activity and is responsible for maintaining eye lens transparency. Synthetic peptides which corresponded to the putative substrate-binding site of alphaAC have been reported to prevent aggregation of proteins [Sharma, K. K., et al. (2000) J. Biol. Chem. 275, 3767-3771]. In this study, we found that these peptides, alphaAC(70-88), the peptide corresponding to amino acids 70-88 of alphaAC (KFVIFLDVKHFSPEDLTVK), and alphaAC(71-88), suppressed the amyloid fibril formation of amyloid beta protein (Abeta). On the other hand, while alphaAC(71-88) exhibited chaperone-like activity toward insulin, alphaAC(70-88) and alphaAC(70-88)K70D promoted rapid growth of aggregates consisting of insulin and these peptides in their solution mixtures. Interestingly, we found that alphaAC(71-88) itself can also form amyloid fibrils. It is possible that the chaperone-like activity of the alphaAC peptides is potentially related to their propensity for amyloid fibril formation. Analysis of variants of the alphaAC peptides suggested that F71 is important for amyloid formation, and interestingly, this same residue has previously been found to be essential for chaperone-like activity. Amyloid fibril formation was also observed with the shorter peptide, alphaAC(70-76)K70D, showing that the ability to form amyloid fibrils is maintained even with significant deletion of the C-terminal sequence. The formation of amyloid fibril was suppressed in alphaAC(70-88), suggesting that the K70 in the substrate binding site may play a role in suppressing the amyloid fibril formation of alphaAC, which agreed with recent proposals about the presence of an aggregation suppressor in the region flanking aggregation-prone hydrophobic sequences.


Sujet(s)
Amyloïde/composition chimique , Fragments peptidiques/composition chimique , Chaine A de la cristalline alpha/composition chimique , Dichroïsme circulaire , Insuline/composition chimique , Microscopie à force atomique , Liaison aux protéines
13.
Biochemistry ; 45(28): 8556-61, 2006 Jul 18.
Article de Anglais | MEDLINE | ID: mdl-16834329

RÉSUMÉ

Escherichia coli heat shock protein ClpB disaggregates denatured protein in cooperation with the DnaK chaperone system. Several studies showed that the N-terminal domain is essential for the chaperone activity, but its role is still largely unknown. The N-terminal domain contains two structurally similar subdomains, and conserved amino acids Thr7 and Ser84 share the same position in two apparent sequence repeats. T7A and S84A substitutions affected chaperone activity of ClpB without significantly changing the native conformation [Liu, Z. et al. (2002) J. Mol. Biol. 321, 111-120]. In this study, we aimed to better understand the roles of several conserved amino acid residues, including Thr7 and Ser84, in the N-terminal domain. We investigated the effects of mutagenesis on substrate binding and conformational states of ClpB N-terminal domain fragment (ClpBN). Fluorescence polarization analysis showed that the T7A and S84A substitutions enhanced the interaction between ClpBN and protein aggregates. Interestingly, further analyses suggested that the mechanisms by which they do so are quite different. For T7A substitution, the increased substrate affinity could be due to a conformational change in the hydrophobic core as revealed by NMR spectroscopy. In contrast, for S84A, increased substrate binding would be explained by a unique conformational state of this mutant as revealed by pressure perturbation analysis. The thermal transition temperature of the S84A mutant, monitored by DSC, was 6.1 degrees C lower than that of wild-type. Our results revealed that conserved amino acids Thr7 and Ser84 both participated in maintaining the conformational integrity of the ClpB N-terminal domain.


Sujet(s)
Protéines Escherichia coli/composition chimique , Protéines du choc thermique/composition chimique , Séquence d'acides aminés , Séquence conservée , Endopeptidase Clp , Protéines Escherichia coli/génétique , Protéines du choc thermique/génétique , Spectroscopie par résonance magnétique , Données de séquences moléculaires , Structure tertiaire des protéines , Sérine/composition chimique , Spécificité du substrat , Thréonine/composition chimique
14.
Cancer Res ; 64(20): 7201-4, 2004 Oct 15.
Article de Anglais | MEDLINE | ID: mdl-15492233

RÉSUMÉ

Metastasis is a major factor associated with poor prognosis in cancer, but little is known of its molecular mechanisms. Although the clinical behavior of soft tissue sarcomas is highly variable, few reliable determinants of outcome have been identified. New markers that predict clinical outcome, in particular the ability of primary tumors to develop metastatic tumors, are urgently needed. Here, we have chosen leiomyosarcoma as a model for examining the relationship between gene expression profile and the development of metastasis in soft tissue sarcomas. Using cDNA microarray, we have identified a gene expression signature associated with metastasis in sarcoma that allowed prediction of the future development of metastases of primary tumors (Kaplan-Meier analysis P = 0.001). Our finding may aid the tailoring of therapy for individual sarcoma patients, where the aggressiveness of treatment is affected by the predicted outcome of disease.


Sujet(s)
Léiomyosarcome/génétique , Léiomyosarcome/secondaire , Sarcomes/génétique , Sarcomes/secondaire , Analyse de profil d'expression de gènes , Humains , Léiomyosarcome/métabolisme , Léiomyosarcome/anatomopathologie , Séquençage par oligonucléotides en batterie , Pronostic , Sarcomes/métabolisme , Sarcomes/anatomopathologie
15.
Nucleic Acids Res ; 30(22): 4937-44, 2002 Nov 15.
Article de Anglais | MEDLINE | ID: mdl-12433997

RÉSUMÉ

In vitro compartmentalisation (IVC), a technique for selecting genes encoding enzymes based on compartmentalising gene translation and enzymatic reactions in emulsions, was used to investigate the interaction of the DNA cytosine-5 methyltransferase M.HhaI with its target DNA (5'-GCGC-3'). Crystallography shows that the active site loop from the large domain of M.HhaI interacts with a flipped-out cytosine (the target for methylation) and two target recognition loops (loops I and II) from the small domain make almost all the other base-specific interactions. A library of M.HhaI genes was created by randomising all the loop II residues thought to make base-specific interactions and directly determine target specificity. The library was selected for 5'-GCGC-3' methylation. Interestingly, in 11 selected active clones, 10 different sequences were found and none were wild-type. At two of the positions mutated (Ser252 and Tyr254) a number of different amino acids could be tolerated. At the third position, however, all active mutants had a glycine, as in wild-type M.HhaI, suggesting that Gly257 is crucial for DNA recognition and enzyme activity. Our results suggest that recognition of base pairs 3 and 4 of the target site either relies entirely on main chain interactions or that different residues from those identified in the crystal structure contribute to DNA recognition.


Sujet(s)
DNA-Cytosine Methylases/composition chimique , DNA-Cytosine Methylases/génétique , Acides aminés/génétique , Séquence nucléotidique , Sites de fixation , Codon , ADN/composition chimique , ADN/métabolisme , DNA-Cytosine Methylases/métabolisme , Émulsions , Banque de gènes , Modèles génétiques , Modèles moléculaires , Mutation , Biosynthèse des protéines , Structure tertiaire des protéines , Spécificité du substrat , Transcription génétique
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE